Poster Presentation ESA-SRB 2023 in conjunction with ENSA

Stereotactic Body Radiation Therapy for Conservative Management of Pancreatic Insulinoma in an 85-Year-Old Male with hypoglycaemia unawareness: A Case Study (#326)

Lauren Moll 1 , Thomas Dover 1 , Kate Haigh 1
  1. Ipswich Hospital, Ipswich, QLD, Australia

Pancreatic insulinomas are rare functional neuroendocrine tumours which cause excessive insulin release and recurrent hypoglycaemia. Diagnosis can be challenging, with the 3 day fast test a significant burden on patients and resources.  Surgery is the mainstay of treatment, with medical therapy used for bridging or for non-surgical management. This is the case of an 85 year old male referred for a vague history of hypoglycaemia. His background included smoldering myeloma, non-small cell lung cancer, epilepsy, and chronic lower limb lymphoedema. After a difficult and delayed diagnosis of insulinoma, he poorly tolerated medical therapy. After MDT discussion, conservative treatment with Stereotactic Body Radiation Therapy (SBRT) was used.

The diagnosis of insulinoma was complicated by a recent misdiagnosis of epilepsy and hypoglycaemic unawareness with no strong evidence of Whipple’s triad.  Diagnosis was made after an unrelated admission in which a hypoglycaemic seizure occurred with biochemistry revealing low glucose (2.5 mmol/L), elevated S-Insulin (22 U/L), pro-insulin (>100 pmol/l) and C-Peptide (1.6 nmol/L) with low beta-hydroxbutyrate (0.04 mmol/L). Magnetic resonance imaging revealed 2.3 cm pancreatic head lesion, which was intensely avid on DOTATATE PET.

The patient was commenced on Diaxoxide at 200 mg twice daily however dosing proved difficult due to fluid overload and renal dysfunction and careful titration was required with the use of Continuous Glucose Monitoring (CGM). Given the patient's age, surgical risk and difficulty with diazoxide, a multidisciplinary team opted for conservative management with SBRT. The patient responded well to SBRT, experiencing reduced hypoglycemia. Gradually tapering off diazoxide over three months post-treatment, he continues under long-term observation.

In conclusion, this case underscores the promise of SBRT as a viable non-surgical alternative for managing insulinomas patients with substantial surgical risks. Additionally, it underscores the importance of considering hypoglycemia unawareness when initially attempting to establish Whipple’s Triad in the investigation of non-diabetic hypoglycaemia.

  1. Badiu C MD, PhD. WILLIAMS TEXTBOOK OF ENDOCRINOLOGY. Acta Endocrinol (Buchar). 2019 Jul-Sep;15(3):416. doi: 10.4183/aeb.2019.416. PMCID: PMC6992389.
  2. Vella, A. (2022). Insulinoma. In: D M Nathan & K Rubinow (Eds) UpToDate, Waltham, MA. (Accessed 3 May 2023)
  3. Halsall D.J, Mangi M, Soos M, et al. Hypoglycemia due to an insulin binding antibody in a patient with an IgA-kappa myeloma.  J Clin Endocrinol Metab . 2007;92:2013–2016. PMID: 17405845
  4. Merlo C, Wimpfheimer C, Muser J, Keller U. Hypoglykämie und multiples Myelom [Hypoglycemia and multiple myeloma]. Schweiz Med Wochenschr. 1992 Oct 24;122(43):1622-6. German. PMID: 1439683.
  5. Waldron-Lynch F, Inzucchi SE, Menard L, Tai N, Preston-Hurlburt P, Hui P, McClaskey J, Hagopian WA, Meffre E, Marks PW, Wen L, Herold KC. Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma. J Clin Endocrinol Metab. 2012 Dec;97(12):4317-23. doi: 10.1210/jc.2012-2388. Epub 2012 Oct 16. PMID: 23074233; PMCID: PMC3513536.
  6. Lichtman MA, Balderman SR. Unusual Manifestations of Essential Monoclonal Gammopathy. II. Simulation of the Insulin Autoimmune Syndrome. Rambam Maimonides Med J. 2015 Jul 30;6(3):e0027. doi: 10.5041/RMMJ.10212. PMID: 26241232; PMCID: PMC4524400.
  7. AM Dizon, S Kowalyk, B Hoogwerf, Neuroglycopenic and other symptoms in patients with insulinomas, The American Journal of Medicine, 106;3 307-310
  8. A Mitrakou et al. Reversibility of Unawareness of Hypoglycemia in Patients with Insulinomas N Eng J Med 1993; 329:834-839
  9. Nosakova L, Banovcin P, Duricek M, Uhrik P, Bozikova J, Demeter M, Hyrdel R. Phenomenon of hypoglycemia unawareness in patients with insulinoma - single center experience. Neuro Endocrinol Lett. 2021 Dec 21;42(8):522-527. Epub ahead of print. PMID: 35490419.
  10. Sugawa T, Murakami T, Yabe D, Kashima R, Tatsumi M, Ooshima S, Joo E, Wada K, Yoshizawa A, Masui T, Nakamoto Y, Yamauchi Y, Kodama Y, Iemura Y, Ogura M, Yasoda A, Inagaki N. Hypoglycemia Unawareness in Insulinoma Revealed with Flash Glucose Monitoring Systems. Intern Med. 2018 Dec 1;57(23):3407-3412. doi: 10.2169/internalmedicine.1173-18. Epub 2018 Aug 10. PMID: 30101920; PMCID: PMC6306522.
  11. Contessa JN, et al. RADIOTHERAPY FOR PANCREATIC NEUROENDOCRINE TUMORS. . Int J Rad Oncology 2009 75;4 1196-2000
  12. Strosberg J et al. Effective Treatment of Locally Advanced Endocrine Tumors of the Pancreas with Chemoradiotherapy. Neuroendocriniology 2007; 85:216-220
  13. Huscher CG, Mingoli A, Sgarzini G, Mereu A, Gasperi M. Image-guided robotic radiosurgery (CyberKnife) for pancreatic insulinoma: is laparoscopy becoming old? Surg Innov. 2012 Mar;19(1):NP14-7.
  14. Alsuhaibani AA & Hassan TS. Curative treatment of pancreatic functioning insulinoma with stereotactic ablative radiation therapy: case report. Int Surj J. 2022 Jan;9(1):181-184